<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533620</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HNCNS-2020-46</org_study_id>
    <nct_id>NCT04533620</nct_id>
  </id_info>
  <brief_title>Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>Predictive-Model Based Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma: A Phase 2 Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase 2 trial with 2 groups (control group vs experimental group).&#xD;
      Patients with locally recurrent nasopharyngeal carcinoma (LR-NPC) assigned to the control&#xD;
      group will receive standardized carbon-ion radiotherapy (CIRT). For patients assigned to the&#xD;
      experimental group, a predictive model will be used to predict the chance of developing&#xD;
      mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription&#xD;
      will be given. The primary endpoint of the study is to compare the 2-year progression-free&#xD;
      survival (PFS) between 2 groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase 2 trial with 2 groups (control group vs experimental group).&#xD;
      Patients with locally recurrent nasopharyngeal carcinoma (LR-NPC) assigned to the control&#xD;
      group will receive standardized CIRT with a dose of 63 gray equivalent (GyE) in 21 fractions&#xD;
      (fx). This regimen was obtained from our previous phase 1 (dose escalation) study. For&#xD;
      patients assigned to the experimental group, a predictive model will be used to predict the&#xD;
      chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and&#xD;
      individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66&#xD;
      GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal&#xD;
      necrosis, respectively. The primary endpoint of the study is to compare the 2-year&#xD;
      progression-free survival (PFS) between 2 groups. The secondary endpoints include 2-year&#xD;
      overall survival (OS), local progression-free survival, regional progression-free survival,&#xD;
      distant metastasis-free survival, toxicities and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From randomization to death or disease progression, a median of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to death, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression-free survival</measure>
    <time_frame>From randomization to local failure, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression-free survival</measure>
    <time_frame>From randomization to regional failure, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>From randomization to distant metastasis, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of radiation-induced acute toxicity evaluated by CTCAE 5.0</measure>
    <time_frame>Within 3 months after initiation of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of radiation-induced late toxicity evaluated by CTCAE 5.0</measure>
    <time_frame>Three months after initiation of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by questionnaires evaluated using EORTC-Q30 questionnaire.</measure>
    <time_frame>Throughout the study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by questionnaires evaluated using EORTC-H&amp;N35 questionnaire.</measure>
    <time_frame>Throughout the study, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Locally Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Standardized CIRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individualized CIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standardized CIRT</intervention_name>
    <description>CIRT with a dose of 63 GyE/21 fx</description>
    <arm_group_label>Standardized CIRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Individualized CIRT</intervention_name>
    <description>A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.</description>
    <arm_group_label>Individualized CIRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 17-70 years.&#xD;
&#xD;
          -  Pathologically diagnosed as WHO type 2/3 nasopharyngeal carcinoma.&#xD;
&#xD;
          -  Failed previous definitive radiotherapy at least 6 months ago.&#xD;
&#xD;
          -  Only had 1 previous course of radiotherapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score: 0-1.&#xD;
&#xD;
          -  Adequate laboratory values within 30 dyas of enrollment to study defined as follows:&#xD;
             1) neutrophil &gt; 2000/mm^3; 2) platelet &gt; 100,000/mm^3; 3) total bilirubin &lt; 1.5mg/dl;&#xD;
             4) alanine aminotransferase/aspartate aminotransferase &lt; 1.5 upper limit of normal; 5)&#xD;
             SCr &lt; 1.5mg/dl; creatinine clearance rate &gt; 60ml/min.&#xD;
&#xD;
          -  Willing to accept adequate contraception for women with childbearing potential.&#xD;
&#xD;
          -  Willing to sign the written informed consent; Informed consent must be signed before&#xD;
             the enrollment in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastasis.&#xD;
&#xD;
          -  Without measurable lesion.&#xD;
&#xD;
          -  Previous history of malignant tumor (within 5 years) or simultaneous existence of&#xD;
             multiple primary tumors.&#xD;
&#xD;
          -  Accompanied with severe major organ dysfunction.&#xD;
&#xD;
          -  Presence of mental disease that may influence the understanding of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiade J Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Kong, MD</last_name>
    <phone>+8602138296666-53516</phone>
    <email>lin.kong@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyi Hu, MD, PhD</last_name>
    <phone>+8602138296666-53516</phone>
    <email>jiyi.hu@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Kong, MD</last_name>
      <email>lin.kong@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiyi Hu, MD</last_name>
      <email>jiyi.hu@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jiade J Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Jiade J. Lu</investigator_full_name>
    <investigator_title>Prof. Jiade J. Lu</investigator_title>
  </responsible_party>
  <keyword>Locally recurrent nasopharyngeal carcinoma</keyword>
  <keyword>Individualized carbon-ion radiotherapy</keyword>
  <keyword>Predictive model of mucosal necrosis</keyword>
  <keyword>Survival</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data including baseline characteristics, treatment information and follow-up data on toxicity, survival and disease control will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 5 years after the publication of the study.</ipd_time_frame>
    <ipd_access_criteria>Data may be shared with radiation oncologists who are interested in examining the efficacy and toxicity of locally recurrent nasopharyngeal carcinoma patients treated with particle beam radiotherapy. Detailed study protocol should be emailed along with the request of the data. We may carefully review the study protocol, and data will only be shared with well-designed studies.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

